Results 211 to 220 of about 9,741 (297)

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

open access: yesChronic Diseases and Translational Medicine, Volume 12, Issue 2, Page 85-99, June 2026.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves   +8 more
wiley   +1 more source

In Situ Hybridization Chain Reaction and Immunohistochemical Labeling of the Octopamine Production Pathway in the Central Nervous System of Lymnaea stagnalis

open access: yesJournal of Comparative Neurology, Volume 534, Issue 6, June 2026.
Octopaminergic neurons in the central nervous system of Lymnaea stagnalis were mapped using three complementary markers: mRNA, enzyme, and neurotransmitter. While substantial overlap was observed, discrepancies revealed neuroanatomical complexities, reinforcing the value of combining HCR and IHC for a more robust interpretation of neurotransmitter ...
Victoria Tweedie‐Pitre   +2 more
wiley   +1 more source

Structural and Functional Imaging of Motor Outcomes in Twins With Perinatal Stroke: A Case Report

open access: yesAnnals of the Child Neurology Society, Volume 4, Issue 2, Page 150-158, June 2026.
ABSTRACT Background Perinatal arterial ischemic stroke (AIS) affects 1 in 4000 live births. Dystonia, affecting ~20% of children following AIS, is characterized by involuntary muscle contractions and abnormal movements. Why some develop dystonia post AIS, while others do not, remains unclear.
Prisca Hsu   +8 more
wiley   +1 more source

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

open access: yesEuropean Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy